IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 3684 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   [PDF Not available] *
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   Abstract
   Introduction
   Material and Methods
   Results
   Comments
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed6148    
    Printed87    
    Emailed3    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal

 


 
SHORT COMMUNICATION
Year : 1993  |  Volume : 59  |  Issue : 1  |  Page : 8-10

Treatment of pompholyx with dapsone




Correspondence Address:
R P Singh


Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

  Abstract 

Seventy six patients having pompholyx of 1 month to 2 years duration were treated with dapsone (DDS) initially with 4 mg/kg/day in two divided doses till clearance of lesions occurred and then with 2 mg/kg/day for a period of 2 weeks. Complete clearance of lesions occurred in all cases in 4 to 18 days (average 7.62 days). Relapse was noted in 4 cases, only one of which required long term maintenance dose for 3 months. A control group of 16 patients were treated with placebo and saline compresses for 3 weeks. Only 3 cases of this group showed clearance of the lesions.


Keywords: Pompholyx, Dapsone


How to cite this article:
Singh R P, Snehi P S. Treatment of pompholyx with dapsone. Indian J Dermatol Venereol Leprol 1993;59:8-10

How to cite this URL:
Singh R P, Snehi P S. Treatment of pompholyx with dapsone. Indian J Dermatol Venereol Leprol [serial online] 1993 [cited 2019 Jul 18];59:8-10. Available from: http://www.ijdvl.com/text.asp?1993/59/1/8/3866



  Introduction Top


Pompholyx is a term given to Eczema of palms and soles which is modified by its special site and in which oedema fluid accumulates to form visible vesicle and bullae. It is nonspecific type of reaction in response to a number of different eliciting and provoking factors. The treatment of acute phase is with saline soaks with or without topical and systemic antibacterial agents. Chronic and relapsing cases require topical and rarely systemic steroids but results of most of the therapeutic regimes were found to be unsatisfactory more so in chronic and relapsing variety. We are reporting the results of treatment of pompholyx with DDS including chronic and relapsing cases.


  Material and Methods Top


Ninety two patients having pompholyx were taken up for study after ruling out any associated factors like dermatophytosis, contact dermatitis, septic focus, or drug intake by clinical and routine lab examination. Seventy six were treated with dapsone (DDS) and 16 were taken as control group.

Cases in DDS treated group were initially given DDS in a dose of 4 mg/kg/day in two divided doses (maximum dose given was 100 mg twice daily) till complete clearance of all the lesions. Later these case were given a maintenance dose of 2 mg/kg/day (to a maximum of 100 mg daily) for 2 weeks. No other topical or systemic therapy was given to the patients. The response was recorded as complete clearance of existing lesions and stopping of appearance of new lesions. Patients were observed for relapse. Relapse cases were again treated with same schedule but not taken as fresh case. Sixteen patients were kept in control group and were treated with placebo and saline soaks thrice daily for 3 weeks. Those oases who did not show improvement after 3 weeks were put on DDS but not included in the DDS group.


  Results Top


Age group of patients were from 8 to 37 years but majority (82) were from 20 to 30 years of age. Duration of symptoms were from 1 month to 2 years. Only 4 cases were having symptoms for more than 6 months. Distribution of lesions in patients is as per [Table - 1]. Patients treated with DDS showed complete clearance of lesions in 4 to 18 days (average 7.62 days) [Figure - 1][Table - 2]

Relapse occurred in 4 cases after 2 weeks of discontinuation of therapy. They were again treated with DDS with complete clearance of lesions. One case came with repeated relapses who was finally given DDS 100 mg daily for 3 months with no further relapses in past 6 months. No severe adverse effect to DDS therapy were noticed during study. The control group showed clearance of lesions of only 3 cases in 3 weeks therapy. The non responding cases were treated with DDS with good response but these cases of control group were not included in DDS group.


  Comments Top


Dapsone is one of the main drugs used in leprosy however, it has also proved a very valuable drug in the management of a wide range of dermatoses. Its mode of action is not fully understood but many of the diseases found empirically to respond to this drug have in common the involvement of either polymorphs or immune complexes. [1],[2] It is effective in the management of a few vesiculobullous disorders like dermatitis herpetiformis, subcorneal pustular dermatosis, and pemphigoid. Keeping the above factors in view dapsone was tried in pompholyx, which also has an immunological basis of origin and found very effective in this study.

 
  References Top

1.Pye RJ, Roberts SOB, Champion RH. Systemic therapy. In : Textbook of Dermatology (Rook A, Wilkinson DS, Ebling FJG, eds), 4th edn. Oxford: Blackwell Scientific, 1989; 2525.  Back to cited text no. 1    
2.Lang PG Jr. Sulphones and sulphonamides in Dermatology today. J Am Acad Dermatol 1:479.  Back to cited text no. 2    


    Figures

[Figure - 1]

    Tables

[Table - 1], [Table - 2]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow